Download Ling-Ming Tseng

Curriculum Vitae
Name:
Ling-Ming Tseng, MD
Attending Surgeon,
Division of General Surgery,
Department of Surgery, Veterans General Hospital-Taipei,
Associate professor, National Yang-Ming University,
Associate professor, National Defense Medical Center
Taiwan, Republic of China
Education: 1982 .08 – 1989.07
National Defense Medical Center M.D.
Address of affiliated institution: No.201, Sec. 2, Shih-Pai Rd.(Shi-Pai Rd.). Taipei (11217), Taiwan, R.O.C.
Surgical & Research Training:
1992-1996 Surgical Resident in Veterans General Hospital, Taipei
1996-1997 Chief Resident in Surgery in Veterans General Hospital, Taipei, ROC
1998-
Attending Surgeon
Division of General Surgery, Department of Surgery,
Veterans General Hospital-Taipei, Taiwan, ROC
2005.12 -2006.11
Visiting Scientist of Department of Surgical Oncology & Department of Molecular&
Cellular Oncology, MD Anderson Cancer Center, the University of Texas, USA
Current Appointments:
1998-
Attending Surgeon in Division of General Surgery, Department of Surgery, Veterans
General Hospital-Taipei
1998Committeeman of Breast Cancer Committee, Taiwan Cooperative Oncology Group,
Division of Cancer Research, National Health Research Institutes
2000-2009 Secretary General of Taiwan association of endocrine surgeons
2007-2010 Council of The Breast Cancer Society of Taiwan
2009Council of Taiwan association of endocrine surgeons
2010Secretary General of The Breast Cancer Society of Taiwan
Certification:
1996
Chinese Board of Surgery
1997
Chinese Board of Surgical Gastroenterology
1999
Chinese Board of Surgical Breast
2000
Chinese Board of Surgical endocrinology
2005-2006 Visiting Scientist of Molecular & cellular Oncology, Surgical Oncology, MD Anderson
Cancer Center
1
2012
The Board of Surgical Oncology of the Chinese Oncology Society and Taiwan Surgical
Association
Membership in Medical and Scientific Society:
1.Taiwan Surgical Association
2.Taiwan Association of Gastrointestinal Surgery
3.Taiwan Association of Endocrine Surgeons
4.The Breast Cancer Society of Taiwan
5.The Chinese Oncology Society
Textbook
1. Endocrine Surgery Principles and Practice
Hubbard, Johnathan; Inabnet, William B.; Lo,
Chung-Yau (Eds.) Springer Specialist Surgery Series
2. Pain Management Yearbook 2013 Joav Merrick, MD, MMedSci, DMSc (Eds.) Pediatrics, Child and
Adolescent Health
Awards
1.
2.
3.
4.
5.
6.
7.
(Pub. Date: 2014 - 3rd Quarter)
2014 Excellent paper presentation of breast of Surgery
2013 Excellent paper presentation of breast of Surgery
2013 Outstanding Paper Award of Merck
2013 Excellent MD Physician Award of Taipei Veterans General Hospital
2012 Second Medical Innovation Award of Taipei Veterans General Hospital
2012 Excellent paper presentation of breast of Surgery
2012 Outstanding Paper Award of Merck
Publications (*correspondence):
1.
Wu YT, Chen ST, Chen CJ, Kuo YL, Tseng LM, Chen DR, Kuo SJ, Lai HW. Breast cancer arising
within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy.
World J Surg Oncol. 2014 Nov 10;12(1):335(I F=1.20)
2.
Chou HP, Tseng LM Outcome of mammography screening in Taiwan J Chin Med Assoc. 2014
Oct;77(10):503-4
Liu CY, Hung MH, Wang DS, Chu PY, Su JC, Teng TH, Huang CT, Chao TT, Wang CY, Shiau CW,
3.
Tseng LM*, Chen KF. Tamoxifen induces apoptosis through cancerous inhibitor of protein
phosphatase 2A dependent phospho-Akt inactivation in estrogen-receptor negative human breast
cancer cells. Breast Cancer Res. 2014 Sep 17;16(5):431. (I F=5.881；R/C=25/202，Oncology)
4.
5.
Liang SY, Wu SF, Chao TC, Tseng LM, Wu WW, Wang TJ, Lu YY. The Impact of Pain on the
Quality of Life of Taiwanese Oncology Patients. Pain Manag Nurs. 2014 Sep 3. pii:
S1524-9042(14)00093-9. (I F=1.787)
Yeh DC, Chen DR, Chao TY, Chen SC, Wang HC, Rau KM, Feng YH, Chang YC, Lee KD, Ou-Yang
F, Kuo WH, Chang KJ, Lin YC, Tseng LM*, Hou MF. EORTC QLQ-BM22 Quality of Life
Evaluation and Pain Outcome in Patients with Bone Metastases from Breast Cancer Treated with
2
Zoledronic Acid. In Vivo. 2014 09-10;28(5):1001-1004
(I F=1.148)
6.
Noomhorm N, Chang CJ, Wen CS, Wang JY, Chen JL, Tseng LM, Chen WS, Chiu JH, Shyr YM In
vitro and in vivo effects of xanthorrhizol on human breast cancer mcf-7 cells treated with tamoxifen. J
Pharmacol Sci. 2014;125(4):375-85 (I F=3.007；R/C=76/254，Pharmacology & Pharmacy)
7.
Chiu JH, Chang CJ, Wu JC, Liu HJ, Wen CS, Hsu CH, Chen JL, Tseng LM*, Chen WS, Shyr YM.
Screening to identify Commonly Used Chinese Herbs that affect ERBB2 and ESR1 Gene Expression
using the Human Breast Cancer MCF-7 Cell Line. Evidence-Based Complementary and Alternative
Medicine Epub 2014 May 27 (I F=1.722；R/C=8/22，INTEGRATIVE & COMPLEMENTARY
MEDICINE)
8.
Liu CY, Su JC, Ni MH, Tseng LM, Chu PY, Wang DS, Tai WT, Kao YP, Hung MH, Shiau CW, Chen
KF. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1
expression and induces apoptosis in human breast cancer cells. Breast Cancer Res Treat. 2014
Jul;146(1):71-84. (I F=5.872；R/C=26/197，ONCOLOGY)
9.
Fu CH, Lin RJ, Yu J, Chang WW, Liao GS, Chang WY, Tseng LM, Tsai YF, Yu JC, Yu AL A
novel oncogenic role of inositol phosphatase SHIP2 in ER-Negative breast cancer stem cells:
Involvement of JNK/Vimentin activation. Stem Cells. 2014 May 6. doi: 10.1002/stem.1735
Hung MH, Liu CY, Shiau CY, Hsu CY, Tsai YF, Wang YL, Tai LC, King KL, Chao TC, Chiu JH, Su
10.
CH, Lo SS, Tzeng CH, Shyr YM, Tseng LM* Effect of Age and Biological Subtype on the Risk and
Timing of Brain Metastasis in Breast Cancer Patients. PLoS ONE 9(2): e89389 (I F=3.730；
R/C=7/56，MULTIDISCIPLINARY SCIENCES)
11.
Chen JL, Chang CJ, Wang JY, Wen CS, Tseng LM, Chang WC, Noomhorm N, Liu HJ, Chen WS,
Chiu JH, Shyr YM In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer
MCF-7 Cells Treated With Tamoxifen. Integr Cancer Ther. 2014 Feb 12;13(3):226-239. (I F=2.354
；R/C=4/22 in Integrative & Complementary Medicine | 108/196 in Oncology)
12.
13.
Cramarossa G, Zeng L, Zhang L, Tseng LM, Hou MF, Fairchild A, Vassiliou V, Jesus-Garcia R,
El-Din MA, Kumar A, Forges F, Chie WC, Sahgal A, Lam H, Pulenzas N, Chow E Predictive factors
of overall quality of life in advanced cancer patients using EORTC QLQ-C30. Expert Rev
Pharmacoecon Outcomes Res. 2013 Dec 10.
Chao TC, Chen DR, Chao TY, Chen SC, Yeh DC, Wang HC, Huang WT, Rau KM, Chang KJ, Yang
TL, Lee KD, Tai CJ, Tseng LM, Hou MF Quality of Life Assessment in Taiwanese Patients with
Bone Metastases from Breast Cancer Receiving Zoledronic Acid. Anticancer Res. 2013
Dec;33(12):5543-5547. (I F=1.872)
14.
Lan YC, Chang CL, Sung MT, Yin PH, Hsu CC, Wang KC, Lee HC, Tseng LM*, Chi CW.
Zoledronic Acid-induced Cytotoxicity Through Endoplasmic Reticulum Stress Triggered
REDD1-mTOR Pathway in Breast Cancer Cells. Anticancer Res. 2013 Sep;33(9):3807-14. (I
F=1.872)
15.
Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW, Chen KF. Novel sorafenib
analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer
cells. Breast Cancer Research 2013 Aug 12;15(4):R63 (I F=5.872；R/C=26/197，ONCOLOGY)
3
16.
Tsai CH, Yang CW, Wang JY, Tsai YF, Tseng LM*, King KL, Chen WS, Chiu JH, Shyr YM
Timosaponin AIII Suppresses Hepatocyte Growth Factor-Induced Invasive Activity through Sustained
ERK Activation in Breast Cancer MDA-MB-231 Cells. Evid Based Complement Alternat Med. Epub
2013 Jun 25.
17.
18.
Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa
L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G,
Pusztai L. Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in
Early Stage Breast Cancer and Evaluation of βIII-Tubulin Expression as a Predictive Marker.
Oncologist. 2013;18(7):787-94
Wong E, Chow E, Zhang L, Bedard G, Lam K, Fairchild A, Vassiliou V, Alm El-Din MA,
Jesus-Garcia R, Kumar A, Forges F, Tseng LM, Hou MF, Chie WC, Bottomley A. Factors influencing
health related quality of life in cancer patients with bone metastases
J Palliat Med. 2013
Aug;16(8):915-21
19.
20.
Lai HW, Tseng LM, Chang TW, Kuo YL, Hsieh CM, Chen ST, Kuo SJ, Su CC, Chen DR The
prognostic significance of metaplastic carcinoma of the breast (MCB) - A case controlled comparison
study with infiltrating ductal carcinoma. Breast. 2013 Jun 17
Lam K, Chow E, Zhang L, Wong E, Bedard G, Fairchild A, Vassiliou V, El-Din MA, Jesus-Garcia R,
Kumar A, Forges F, Tseng LM, Hou MF, Chie WC, Bottomley A. Determinants of quality of life in
advanced cancer patients with bone metastases undergoing palliative radiation treatment. Support
Care Cancer. 2013 Jun 19
21.
Huang SM, Chien LY, Tai CJ, Tseng LM, Chen PH, Tai CJ. Increases in Xu Zheng and Yu Zheng
among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies. Evid Based
Complement Alternat Med. pub 2013 Mar 21
22.
Lai HW, Wu HK, Kuo SJ, Chen ST, Tseng HS, Tseng LM, Chen DR. Differences in accuracy and
underestimation rates for 14- versus 16-gauge core needle biopsies in ultrasound-detectable breast
lesions. Asian J Surg. 2013 Apr;36(2):83-8
23.
Lam K, Zeng L, Zhang L, Tseng LM, Hou MF, Fairchild A, Vassiliou V, Jesus-Garcia R, El-Din
MA, Kumar A, Pharmd FF, Chie WC, Sahgal A, Poon M, Chow E. Predictive Factors of Overall
Well-Being Using the EORTC QLQ-C15-PAL Extracted from the EORTC QLQ-C30. J Palliat
Med. 2013 Mar 4.
24.
Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, Li H, Lin YC, Chang HK, Chao TC,
Ouyang F, Hou MF
Distant metastasis in triple-negative breast cancer.
Neoplasma.
2013;60(3):290-4
25.
Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, Chan S, Welcher R, Liu D Biomarker
Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in
Early-stage Breast Cancer. Clin Cancer Res. 2013 Jan 22.
26.
Chen JL, Wang JY, Tsai YF, Lin YH, Tseng LM*, Chang WC, King KL, Chen WS, Chiu JH, Shyr
YM In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated
with tamoxifen and trastuzumab. Menopause. 2013 Jan 21 (IF=3.163；R/C=10/78，OBSTETRICS
& GYNECOLOGY)
4
27.
Hsu HY, Lin TY, Hwang PA, Tseng LM, Chen RH, Tsao SM, Hsu J. Fucoidan induces changes in
the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent
TGFβ receptor degradation in breast cancer. Carcinogenesis. 2013 Jan 18
28.
Ke CC, Liu RS, Yang AH, Liu CS, Chi CW, Tseng LM, Tsai YF, Ho JH, Lee CH, Lee OK.
CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide
therapy. Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):61-71
29.
Lai YC, Hsu CY, Chou YH, Tiu CM, Tseng LM, Wang HK, Chiou HJ. Sonographic presentations of
metaplastic breast cancers. J Chin Med Assoc. 2012 Nov;75(11):589-94.
30. Huang SM, Tai CJ, Lin KC, Tai CJ, Tseng LM, Chien LY. A Comparative Study of Symptoms and
Quality of Life Among Patients With Breast Cancer Receiving Target, Chemotherapy, or Combined
Therapy. Cancer Nurs. 2012 Oct 5
31. Zeng L, Chow E, Bedard G, Zhang L, Fairchild A, Vassiliou V, Alm El-Din MA, Jesus-Garcia R,
Kumar A, Forges F, Tseng LM, Hou MF, Chie WC, Bottomley A. Quality of Life After Palliative
Radiation Therapy for Patients With Painful Bone Metastases: Results of an International Study
Validating the EORTC QLQ-BM22. Int J Radiat Oncol Biol Phys. 2012 Jul 3 (IF 4.105)
32. Zeng L, Chow E, Zhang L, Tseng LM, Hou MF, Fairchild A, Vassiliou V, Jesus-Garcia R, El-Din MA,
Kumar A, Forges F, Chie WC, Bedard G, Bottomley A. An international prospective study
establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in
cancer patients with bone metastases. Support Care Cancer. 2012 May 6
33. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in
human triple negative breast cancer cells. Breast Cancer Res. 2012 Apr 26;14(2):R68.
(I F=5.87；R/C= 26/196，ONCOLOGY)
34. Lo WL, Chu PY, Lee TH, Su TL, Chien Y, Chen YW, Huang PI, Tseng LM, Tu PH, Kao SY, Lo JF
A Combined DNA-Affinic Molecule and N-Mustard Alkylating Agent Has an Anti-Cancer Effect and
Induces Autophagy in Oral Cancer Cells. Int J Mol Sci. 2012;13(3):3277-90.
35. Lo WL, Chien Y, Chiou GY, Tseng LM, Hsu HS, Chang YL, Lu KH, Chien CS, Wang ML, Chen YW,
Huang PI, Hu FW, Yu CC, Chu PY, Chiou SH Nuclear localization signal-enhanced RNA
interference of EZH2 and Oct4 in the eradication of head and neck squamous Cell carcinoma-derived
cancer stem cells. Biomaterials. 2012 May;33(14):3693-709.
36. Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen
KH, Chi CW, Chiou SH, Yang DM, Lee CH. Targeting STAT3 Pathway by Cucurbitacin I Diminishes
Self-renewaling and Radiochemoresistant Abilities in Thyroid Cancer-derived CD133+ Cells. J
Pharmacol Exp Ther. 2012 May;341(2):410-23.
37. Chiou GY, Cherng JY, Hsu HS, Wang ML, Tsai CM, Lu KH, Chien Y, Hung SC, Chen YW, Wong CI,
Tseng LM, Huang PI, Yu CC, Hsu WH, Chiou SH Cationic polyurethanes-short branch PEI-mediated
delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties
and in lung adenocarcinoma. J Control Release. 2012 Apr 30;159(2):240-50.
38. Chuang HH, Yang CH, Tsay YG, Hsu CY, Tseng LM, Chang ZF, Lee HH. ROCKII serine 1366
phosphorylation reflects the activation status. Biochem J. 2012 Apr 1;443(1):145-51.
39 Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K,
Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng
LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber
5
RD, Piccart-Gebhart M; on behalf of the NeoALTTO Study Team. Lapatinib with trastuzumab for
HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3
trial.Lancet. 2012 Jan 16.
( I F=39.060；R/C= 2/151，MEDICINE, GENERAL & INTERNAL)
40 Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la
Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi
G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and
trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer
(NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011 Dec 6.
41 Chang CJ, Chien Y, Lu KH, Chang SC, Chou YC, Huang CS, Chang CH, Chen KH, Chang YL, Tseng
LM, Song WS, Wang JJ, Lin JK, Huang PI, Lan YT. Oct4-related cytokine effects regulate tumorigenic
properties of colorectal cancer cells. Biochem Biophys Res Commun. 2011 Oct 19
42 Wu CL, Tiu CM, Chen JD, Tseng LM, Chou YH, Chang CY. Gauzoma of the Breast. Breast J. 2011
Sep 23
43 Yang PS, Yin PH, Tseng LM*, Yang CH, Hsu CY, Lee MY, Horng CF, Chi CW. Rab5A is associated
with axillary lymph node metastasis in breast cancer patients. Cancer Sci. 2011 Sep 3
44 Lai HW, Chien SY, Kuo SJ, Tseng LM, Lin HY, Chi CW, Chen DR. The Potential Utility of Curcumin
in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study
with Herceptin. Evid Based Complement Alternat Med. 2012;2012:486568. Epub 2011 Jun 6
45 Chow E, Nguyen J, Zhang L, Tseng LM, Hou MF, Fairchild A, Vassiliou V, Jesus-Garcia R, El-Din
MA, Kumar A, Forges F, Chie WC, Bottomley A; On behalf of the European Organization for Research
Treatment of Cancer Quality of Life Group. International field testing of the reliability and validity of
the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases.
Cancer. 2011 Aug 11
46 Tseng LM, Yin PH, Yang CW, Tsai YF, Hsu CY, Chi CW, Lee HC Somatic mutations of the
mitochondrial genome in human breast cancers. Genes Chromosomes Cancer. 2011 Jul 11( I F=3.546；
R/C= 65/196，ONCOLOGY)
47 Lu YS, Chen DR, Tseng LM, Yeh DC, Chen ST, Hsieh CM, Wang HC, Yeh HT, Kuo SH, Huang CS.
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally
advanced breast cancer Cancer Chemother Pharmacol. 2011 Jun;67(6):1257-63
48 Yang YP, Chang YL, Huang PI, Chiou GY, Tseng LM, Chiou SH, Chen MH, Chen MT, Shih YH,
Chang CH, Hsu CC, Ma HI, Wang CT, Tsai LL, Yu CC, Chang CJ. Resveratrol suppresses
tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting
the STAT3 axis. J Cell Physiol. 2011 Apr 18
49 Zhang S, Huang WC, Li, P., Guo H, Poh, SB, Brady, S. W., Xiong, Y., Tseng LM, Li SH, Ding Z,
Sahin A, Esteva FJ, Hortobagyi G, Yu D. Combating Trastuzumab Resistance by Targeting Src, a
Common Node Downstream of Multiple Resistance Pathways. Nature Medicine, 2011 Apr;17(4):461-9.
( I F=24.302；R/C=3/290，BIOCHEMISTRY & MOLECULAR BIOLOGY)
50 Lo WL, Yu CC, Chiou GY, Chen YW, Huang PI, Chien CS, Tseng LM, Chu PY, Lu KH, Chang KW,
Kao SY, Chiou SH. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and
neck squamous cell carcinoma stem cells. J Pathol. 2011 Mar;223(4):482-95
51 Yu CC, Chen YW, Chiou GY, Tsai LL, Huang PI, Chang CY, Tseng LM, Chiou SH, Yen SH, Chou
6
MY, Chu PY, Lo WL. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and
neck cancer via stem-like properties ablation. Oral Oncol. 2011 Feb 1.
52 Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou
SH. Cucurbitacin i inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell
lung cancer-derived CD133-positive cells. Cancer. 2011 Jan 10.
53 Yu CC, Chiou GY, Chen YW, Huang PI, Chien CS, Tseng LM, Chu PY, Lu KH, Chang KW, Kao SY,
Chiou SH. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck
squamous cell carcinoma stem cells. J Pathol. 2010 Nov 23
54 Li HY, Chen YJ, Chen SJ, Kao CL, Tseng LM, Lo WL, Chang CM, Yang DM, Ku HH, Twu NF, Liao
CY, Chiou SH, and Chang YL. Induction of insulin-producing cells derived from endometrial
mesenchymal stem-like cells. The Journal of Pharmacology and Experimental Therapeutics, 2010
Dec;335(3):817-29.
55 Yu CC, Lo WL, Chen YW, Huang PI, Hsu HS, Tseng LM, Hung SC, Kao SY, Chang CJ, and Chiou
SH. Bmi-1 Regulates Snail Expression and Promotes Metastasis Ability in Head and Neck Squamous
Cancer-Derived ALDH1 Positive Cells. Journal of Oncology, 2011;2011.
56 Chen YW, Chen KH, Huang PI, Chen YC, Chiou GY, Lo WL, Tseng LM, Hsu HS, Chang KW, and
Chiou SH. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in
head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells. Molecular Cancer
Therapeutics, 2010 Nov: 9(11):2879-92.
57 Chia-Wei Hung, Ying-Jay Liou, Shao-Wei Lu, Ling-Ming Tseng, Chung-Lan Kao, Shih-Jen Chen,
Shih-Hwa Chiou and Charn-Jung Chang. Stem Cell-Based Neuroprotective and Neurorestorative
Strategies. Int. J. Mol. Sci. 2010, 11, 2039-2055
58 Lu YS, Chen DR, Tseng LM, Yeh DC, Chen ST, Hsieh CM, Wang HC, Yeh HT, Kuo SH, Huang
CS. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally
advanced breast cancer. Cancer Chemother Pharmacol.2010 Aug 11
59 Chi-Hsien Peng, Yuh-Lih Chang, Chung-Lan Kao, Ling-Ming Tseng, Chih-Chia Wu , Yu-Chih Chen,
Ching-Yao Tsai, Lin-Chung Woung, Jorn-Hon, Liu, Shih-Hwa Chiou and Shih-Jen Chen. SirT1— A
Sensor for Monitoring Self-Renewal and Aging Process in Retinal Stem Cells. Sensors 2010, 10,
6172-6194
60 Chen YC, Chang CJ, Hsu HS, Chen YW, Tai LK, Tseng LM, Chiou GY, Chang SC, Kao SY, Chiou
SH, Lo WL. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck
squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol. 2010
Mar;46(3):158-65. Epub 2009 Dec 29.
61 Chih-Wei Hsu, Pen-Hui Yin, Hsin-Chen Lee, Chin-Wen Chi, Ling-Ming Tseng* Mitochondrial DNA
Content as a Potential Marker to Predict Response to Anthracycline in Breast Cancer Patients. The
Breast Journal, 2010 1–7
62 Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC,
Ku HH, Chiou SH, Lo WL.
Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in
head and neck squamous cancer. Biochem Biophys Res Commun. 2009 Jul 31;385(3):307-13. Epub
2009 May 18.
63 Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D. ErbB2-mediated Src and signal
transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1
7
and chemoresistance in breast cancer cells. Mol Cancer Res. 2009 Apr;7(4):592-600
64 Jing Lu, Ming Tan, Wen-Chien Huang, Ping Li, Hua Guo, Ling-Ming Tseng, Xiao-Hua Su, Wen-Tao
Yang, Warapen Treekitkarnmongkol, Michael Andreeff, Fraser Symmans, Dihua Yu. Mitotic
Deregulation by surviving in ErbB2-overexpressiong Breast Cancer cells contributes to Taxol
Resistance. Clin Cancer Res. 2009 Feb 15(4) 1327-34
65 Ling-Ming Tseng, Pen-Hui Yin, Yi-Fang Tsai, Chin-Wen Chi, Chew-Wun Wu, Liang-Ming Lee,
Hsin-chen Lee Association between mitochondrial DNA 4,977 bp deletion and HAD(p)H: quinine
oxidoreductase 1C609T polymorphism in human breast tissues. Oncology Report. 2009 21:1169-74
66 Wen-Yi Hung, Jin-Ching Lin, Liang-Ming Lee, Chew-Wun Wu, Ling-Ming Tseng, Pen-Hui Yin,
Chin-Wen Chi, and Hsin-Chen Lee Tandem Duplication/Triplication Correlated with Poly-cytosine
Stretch Variation in Human Mitochondrial DNA D-loop Region. Mutagenesis 2008 Feb,23(2):137-42
67 Wen-Liang Fang, Ling-Ming Tseng, Jui-Yu Chen, See-Ying Chiou, Yi-Hong Chou, Chew-Wun Wu,
Chen-Hsen Lee The Management of High Risk Patients with Primary Hyperparathyroidism —
Minimally Invasive Parathyroidectomy Versus Medical Treatment. Clinical Endocrinology 2008 ,68(4)
520-8
68 Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KU, Neal CL, Mills GB, Hortobagyi GN, Esteva
FJ, Yu D. Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab
Resistance Caused by PTEN Deficiency Clin Cancer Res. 2007 Oct 1;13 (19):5883-8
69 Ling-Min Tseng , Jui-Yu Chen , Justin Ging-Shing Won, Hsiao-Shan Tseng, An-Han Yang, Sine-E
Wang, Chen-Hsen Lee The Role of Intra-arterial Calcium Stimulation Test with Hepatic Venous
Sampling(IACS) in the Management of Occult Insulinomas Ann Surg Onco 2007 Jul;14(7):2121-7
70 Chang, C. J., Chiu, J. H., Tseng, L. M., Chang C.H. Chien, T. M., Chen, C. C., Wu, C. W., and Lui, W.
Y. Si-Wu-Tang and its constituents promote mammary duct cell proliferation by up-regulation of
HER-2 signaling. Menopause, 13: 967-976, 2006.
71 Chang, C. J., Chiu, J. H. Tseng, L. M, Chang, C.H., Chien, T.M., Wu, C.W., and Lui, W. Y.
Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. Eur J Clin Invest,
36: 588-596, 2006.
72 Chiou, S. Y., Chou, Y. H., Chiou, H. J., Wang, H. K., Tiu, C. M., Tseng, L. M., and Chang, C. Y.
Sonographic features of nonpalpable breast cancer: a study based on ultrasound-guided wire-localized
surgical biopsies. Ultrasound Med Biol, 32: 1299-1306, 2006.
78 Kung, S. P., Lee, C. H., Yang, A. H., Chi, C. W., Tseng, L. M., and Wu, C. W. Expression of c-kit,
Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin. J Chin Med
Assoc, 69: 74-79, 2006.
79 Lai, H. W., Lee, C. H., Chen, J. Y., Tseng, L. M., and Yang, A. H. Insular thyroid carcinoma: collective
analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation
therapy. J Am Coll Surg,203:715-722, 2006.
80 Lee, C. H., Tseng, L. M., Chen, J. Y., Hsiao, H. Y., and Yang, A. H. Primary hyperparathyroidism in
multiple endocrine neoplasia type 1: individualized management with low recurrence rates. Ann Surg
Oncol, 13: 103-109, 2006.
81 Liu, J. M., Wu, H. W., Tiu, C. M., Tseng, L. M., Yen, S. H., Shiau, C. Y., Lan, C., and Li, A. F.
Comprehensive Breast Cancer Adjuvant Digital Summary. J Digit Imaging,2006. 19(3):264-9
82 Tiu, C. M., Chou, Y. H., Chiou, S. Y., Hsu, C. Y., Chen, S. P., Chiang, H. R., Lai, C. R., Tseng, L. M.,
8
Wang, H. K., and Chiou, H. J. Development of a carcinoma in situ in a fibroadenoma: color Doppler
sonographic demonstration. J Ultrasound Med, 25: 1335-1338, 2006.
83 Tseng, L. M., Yin, P. H., Chi, C. W., Hsu, C. Y., Wu, C. W., Lee, L. M., Wei, Y. H., and Lee, H. C.
Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes
Cancer, 45: 629-638, 2006
84 Yang, A. H., Hsu, C. W., Chen, J. Y., Tseng, L. M., Won, G. S., and Lee, C. H. Normocalcemic
primary hyperparathyroidism in patients with recurrent kidney stones: pathological analysis of
parathyroid glands. Virchows Arch, 449: 62-68, 2006
85 Tung,W.H.,Chou Y.H.,Tiu C.M.,Chen S.P.,Chiang H.R.,Tseng L.M.,Chiou H.J.,Chiou S.Y.,Wang
H.K.,Yen C.H. Demonstration of Ductal Carcinoma in Situ with Microcalcification in a Patient with
Augmentation Mammoplasty by Free Silicone Injection J Med Ultrasound,2005, 13:135-139
86 Ta-Chung Chao, Zyting Chu, Ling-Ming Tseng, Tzeon-Jye Chiou, Ruey-Kuen Hsieh, Wei-Shu Wang,
Chueh-Chuan Yen, Muh-Hwa Yang, Jin-Hwang Liu, Po-Min Chen. Paclitaxel in a noval formulation
containing less Cremophor EL as first-line therapy for advanced breast cancer: A phase II trial.
Investigational New Drugs 23: 171-177, 2005.
87 Lee S.M. , Tseng LM. , Lee A.-F., Liu H.-C., Liu T.-Y., Chi C.-W. Polymorphism of estrogen
metabolism genes and cataract Medical hypotheses 2004;63 494-97
88 Tseng LM, Hsu CY, Wang HC, Liu JM, Chang HM, Lo SS, Wu CW, Lui WY, Chi CW Tie-1
tyrosine kinase is an independent prognostic indicator for invasive breast cancer Anticancer
Res. 2001 May-Jun;21(3C):2163-70.
9